Drug Profile
Research programme: metabolic disorders therapy - Immusol
Latest Information Update: 22 Oct 2010
Price :
$50
*
At a glance
- Originator Immusol
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 22 Oct 2010 Discontinued - Preclinical for Metabolic disorders in USA (unspecified route)
- 16 Dec 2008 No development reported - Preclinical for Metabolic disorders in USA (unspecified route)
- 24 Aug 2007 This programme is available for licensing worldwide (http://www.immusol.com)